A c c e p t e d M a n u s c r i p t
Introduction
Although injection drug use (IDU) is the principal mode of hepatitis C virus (HCV) transmission in the United States, 10-40% of persons in many epidemiologic studies have no identifiable parenteral source of infection [1] . Among HIV-infected men who have sex with men (MSM), evidence is accumulating that HCV transmission may be facilitated by traumatic sexual practices [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] and non-injection drug use (NIDU) [12, 13] , in the absence of IDU.
While the epidemiology of HCV among HIV-infected injection drug users is well described, less is known about the prevalence and incidence of HCV among HIV-infected MSM in the United States. A study of HIV-infected male participants in the U.S. AIDS Clinical Trial Group Longitudinal Linked Randomized Trials Cohort found an annualized HCV incidence of 0.5/100 person-years between 1996 and 2008. Notably, 75% of seroconverters reported no history of IDU [14] but this sample might not reflect the diversity of HIV-infected MSM in care.
A study conducted among non-injection drug-using HIV-infected MSM in San Francisco found HCV seroprevalence to decline from 8.7% in 2004 to 4.5% in 2008 [15] . These findings contrast with multiple European studies that have identified an increasing incidence of HCV among HIVinfected MSM [16, 17] . An important barrier to assessing the burden of HCV among HIVinfected MSM in the United States is that rates of initial and repeat HCV antibody (Ab) screening in this population remain low [18] .
Fenway Health, in Boston, Massachusetts, provides care to over 20,000 patients, of whom about 50% are MSM and other sexual and gender minorities [19] . An estimated 96% of HIV-infected men who seek care at Fenway Health identify as MSM. Among the >1,750 HIVinfected MSM in care at Fenway Health, the prevalence of self-reported IDU is < 3%. This large sample of non-injection drug using, HIV-infected MSM, who are engaged in care at a single site, A c c e p t e d M a n u s c r i p t Baseline characteristics were compared between patients who received no HCV Ab testing versus those who received one or more HCV Ab test over the study period. Among all tested patients, the proportion with an HCV Ab-positive result upon initial testing, including those with known HCV prior to entry into care at Fenway Health, provided the baseline HCV prevalence.
For patients with an initial HCV Ab-negative result and at least one repeat HCV Ab test, HCV incidence was calculated by dividing number of seroconversion events by person-time at risk; a 95% confidence interval was calculated assuming a Poisson distribution. Person-time was calculated using the dates of the first negative HCV Ab test and the first positive HCV Ab test.
To account for variable intervals of HCV Ab testing, the date of seroconversion was re-assigned as half-way between the date of the last negative and first positive HCV Ab result, using previously described methods [21, 22] . Bivariate significance testing was completed using Mann-Whitney U tests for continuous variables and χ Among the 1059 men who had at least one HCV Ab test, 38 (4%) were found to have a positive HCV Ab on initial testing, 26 (2%) were known to be HCV-seropositive prior to entry into care, and 995 (94%) were found to have a negative HCV Ab on initial testing. Among the 995 men with an initial negative HCV Ab, 616 (62%) were not re-tested. In comparing the 616 men who only had one HCV Ab test with the 379 men who had ≥ 2 HCV Ab tests, there were no significant differences in race, risk factor for HIV acquisition and initial CD4 + cell count (Table   1 ). However, men with an HIV viral load of up to 10,000 copies/mL were more likely to have >1 HCV Ab test compared with men who had an undetectable HIV viral load (p<0.01).
Of the 379 men who had one or more subsequent HCV Ab tests after an initial negative result, 255 were tested twice, 85 were tested 3 times, and 37 were tested 4 or more times over a maximum 12 year period. The median time between HCV antibody tests was comparable between men who seroconverted (2.5 years) and those who didn't (2.8 years) (p=0.59). Among the 379 men with two or more HCV Ab tests, 27 were diagnosed with HIV infection after entry into care at Fenway Health. We excluded person-time from entry into care at Fenway Health until HIV diagnosis for these 27 men. Twenty-three (6%) of 379 men seroconverted to HCV Ab-A c c e p t e d M a n u s c r i p t Among men with incident or prevalent HCV, 33% reported a history of IDU, 46% reported a history of NIDU, 16% reported no drug use, and substance use history was unknown for 5% (Table 2) . Among non-injection drug users, cocaine was the most commonly reported substance used. The majority of men had a history of at least one STI beside HIV. Men with incident HCV were younger (37 versus 44 years; p<0.01) and a higher proportion had an STI history other than HIV compared to men with prevalent HCV (87% versus 64%; p=0.04).
Sixty-four (74%) men who were seropositive for HCV developed chronic HCV infection (Table 3) Among 51 men with chronic HCV infection who did not initiate treatment or who were treated but did not achieve SVR, the median APRI score was 1.22 (range 0.12-6.09); 22 (43%) had a score < 0.5, 20 (39%) had a score between 0.5-1.5, and 9 (17.6%) had a score > 1.5.
Discussion:
The annualized incidence of HCV among this sample of HIV-infected MSM engaged in primary care in Boston, Massachusetts was 1.63/100 person-years. To our knowledge, this is the [26] . Our findings support the growing body of evidence that the epidemiology of HCV infection may be changing among HIV-infected MSM in the United States. In the absence of IDU, high risk sexual behaviors and NIDU appear to play an important role in transmission. Importantly, since patients and providers may be unaware of the risk of HCV transmission in the setting of these non-traditional risk factors [27, 28] , early screening may be uncommon.
In this study, 9% of HIV-infected MSM did not have a documented HCV Ab test at any point in the study, and 62% had only an initial negative HCV Ab test with no subsequent testing despite long-term follow-up care at this clinic. This low rate of repeat HCV Ab testing may in [29] . In contrast, U.S. HIV primary care guidelines endorse HCV Ab screening at the time of HIV diagnosis but lack recommendations for repeated screening among individuals with a negative HCV Ab test [30] . While baseline screening for HCV will diagnose infection acquired either prior to or at the time of HIV acquisition, HCV acquired after HIV infection is typically clinically silent [31] , and may not be diagnosed until late in its clinical course without rescreening. The Centers for Disease Control and Prevention (CDC) now recommends routine ongoing HCV testing among HIV-infected MSM with high risk sexual behaviors or concomitant ulcerative STIs [32] . CDC also now recommends screening all Americans born between 1945 and 1965 (the "baby boomers") [33] .
In this study, 59% of HIV-infected MSM with chronic HCV infection who underwent treatment achieved SVR, despite a high prevalence of genotype 1 infection and elevated baseline HCV RNA. This SVR rate is higher than previously reported among HIV-infected persons with chronic HCV [34] and may in part be explained by an earlier stage of fibrosis at the time of treatment. A shorter duration of HCV infection at the time of treatment and higher treatment completion rates may also have contributed to the high SVR rate. In addition, much of the earlier data on HCV treatment response rates in coinfected individuals involved patients who were older and of African American ancestry [35, 36] . The high SVR rate observed may reflect more optimal HCV treatment responses with interferon-based treatment among patients who are younger and Caucasian. Finally, provider experience at Fenway Health and the coinfectionspecific referral center may have contributed to increased HCV treatment rates and improved outcomes [37, 38] . Given that the addition of the HCV protease inhibitors improves SVR rates in patients with genotype 1 infection [39] , earlier recognition and treatment of HCV infection may greatly improve outcomes.
Several study limitations should be noted. Data collection was based upon retrospective chart review and may not have captured risk factor data that was undocumented by providers.
Data on alcohol use was not systematically documented and was not included in this analysis.
Data on IDU and NIDU was based upon patient self-report and may have under-estimated the true prevalence of substance use as well as the contribution of substance use to HCV acquisition in this population. However, audio-computer-assisted interview methods are employed at Fenway Health to collect behavioral data [40, 41] and have been shown to be effective in increasing the reporting of risky or undesirable behaviors. Although 96% of HIV-infected men at Fenway Health identify as MSM, current sexual behavior data were not available for all individuals. While all 87 men with HCV were MSM, some non-MSM patients may have been included in the denominator which included all male HIV-infected patients in care, suggesting that annualized HCV incidence might actually be higher for HIV-infected MSM. Nine percent of patients at Fenway Health did not receive an HCV Ab test and the remaining patients had variable HCV Ab testing over the study period, with the majority of patients undergoing a single negative screening test. Thus, we may have under-estimated true HCV Ab prevalence and incidence among HIV-infected MSM at Fenway Health. Given that data was retrospectively collected, we were unable to determine whether patients with incident HCV had recent acute versus chronic HCV infection; thus, some patients may have been miss-classified. Finally, while we included data on baseline CD4 + cell count and HIV viral load in our analyses, we were unable to assess the association between antiretroviral therapy use and HCV Ab testing, disease progression and treatment outcomes.
In the United States and other regions where HIV-infected individuals have access to highly active antiretroviral therapy, HCV is a leading cause of non-AIDS related mortality [42] Increasing evidence supports a high prevalence and incidence of HCV infection among HIVinfected MSM. In order to reduce the morbidity and mortality associated with chronic HIV/HCV coinfection, HIV-infected MSM should receive annual HCV Ab screening to diagnose and treat infection at earlier stages; higher-risk patients should be screened more often [43] . Furthermore, HIV-infected MSM who use recreational drugs and/or engage in unprotected sex should receive education and services related to sexual risk reduction, be offered counseling and treatment for substance use and addiction, and be made aware of non-classic risk factors for HCV. Such preventative interventions are crucial to stemming the ongoing spread of HCV. 
